Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

    Author StockStreetNewsPosted on Categories BiotechTags , , ,

    DUBLIN, April 29, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

    Conference Call Information

    To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma’s website at www.theravance.com, under the Investors section, Events and Presentations.

    A replay of the webcast will be available on Theravance Biopharma’s website for 30 days through June 12, 2024.

    About Theravance Biopharma

    Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference® in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

    For more information, please visit www.theravance.com.

    THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

    YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

    Contact:

    [email protected]

    650-808-4045

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2024-financial-results-on-may-13-2024-302129720.html

    SOURCE Theravance Biopharma, Inc.

    Featured image: Megapixl © Prometeus

    Disclaimer